Tumor necrosis factor alpha is one of the most important cytokines in the pathogenesis of rheumatic diseases, especially rheumatoid arthritis, and is known as a central offender in rheumatoid pathogenesis. The major biological roles of tumor necrosis factor α include: causing joint inflammation and cartilage destruction; inducing the release of other inflammatory cytokines; mediating infection and sepsis, and participating in tumor surveillance. Tumor necrosis factor α blockers can block the biological activity of tumor necrosis factor α through specific binding to tumor necrosis factor α, so as to achieve the purpose of controlling inflammation and sustained relief. The tumor necrosis factor α blockers that have been studied more are infliximab, etanercept and adalimumab. Tumor necrosis factor alpha blockers have been approved by the U.S. Drug and Food Administration for the treatment of rheumatoid arthritis (including juvenile), ankylosing cristatitis, psoriatic arthritis, and Crohn’s disease due to their rapid onset of action, excellent efficacy, ability to delay bone erosion, and fewer adverse effects.